Press Releases

Dyadic Reports 4Q2017 Financial Results

Dyadic International Announces 2017 Year End Results and Recent Developments

$49.1 million of cash, cash equivalents and investment securities as of December 31, 2017
Successfully executed two funded collaborations in 2017 and signed three new collaborations in 2018
Early data generated from our research programs are showing encouraging results for C1 technology
Settlement with the last remaining defendant in…

Dyadic International Appoints Chief Accounting Officer

JUPITER, FL – March 15, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), today announced that Chief Financial Officer Thomas L. Dubinski 
will be on a medical leave of absence, effectively immediately. In Mr. Dubinski’s absence, other executive officers will assume many of Mr. Dubinski’s duties while remaining in their current positions. Ping W. Rawson, the Company’s…

DYADIC INTERNATIONAL TO ANNOUNCE YEAR END 2017 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON TUESDAY MARCH 27, 2018

JUPITER, FL – March 13, 2018 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the year…

Dyadic International, Inc. Announces Research and Development Collaboration with Mitsubishi Tanabe Pharma Corporation To Produce Two Target Proteins in C1

JUPITER, FL – February 27, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic products at commercial scales, today announced that it has entered into a funded proof of concept research collaboration to…

Dyadic International, Inc. Announces Research and Development Collaboration To Produce An Active Ingredient in C1

JUPITER, FL – February 7, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic products at commercial scales, today announced that it has entered into a funded proof of concept research collaboration to…

Dyadic International, Inc. Announces New R&D Agreement

Dyadic International, Inc. Announces Research and Development Collaboration with the Israel Institute for Biological Research (IIBR) to Combat Emerging Diseases & Threats

JUPITER, FL – January 16, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production…

DYADIC INTERNATIONAL APPOINTS NEW BOARD MEMBER

JUPITER, FL – January 3, 2018 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on the development and large-scale manufacture of low cost, better performing biologic vaccines and drugs at flexible commercial scales, today announced the appointment of Barry Buckland, Ph.D., to its Board of Directors, effective January 3rd, 2018.

Dr. Buckland spent 29…

DYADIC INTERNATIONAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS

JUPITER, FL – November 9, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended September 30, 2017.

BUSINESS HIGHLIGHTS AND…

DYADIC INTERNATIONAL TO ANNOUNCE THIRD QUARTER 2017 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON THURSDAY NOVEMBER 9, 2017

JUPITER, FL – October 26, 2017 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, announced today that it will report its financial results for the quarter…

Dyadic International Presentation Now Available for On-Demand Viewing

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation

JUPITER, Fla. October 9, 2017, /PRNewswire/ — Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales,…